Profusa, Inc. (NASDAQ:PFSA) Stock Short Interest Rises 409.3%
by Danessa Lincoln · The Markets DailyProfusa, Inc. (NASDAQ:PFSA – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totaling 160,653 shares, a growth of 409.3% from the September 15th total of 31,545 shares. Approximately 31.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 9,017,408 shares, the short-interest ratio is presently 0.0 days.
Analysts Set New Price Targets
A number of research firms have recently weighed in on PFSA. Wall Street Zen raised shares of Profusa to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings raised Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Profusa has a consensus rating of “Sell”.
View Our Latest Analysis on PFSA
Insider Buying and Selling at Profusa
In other news, major shareholder Financial Lp Hrt sold 10,602 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total value of $37,743.12. Following the sale, the insider directly owned 18,549 shares in the company, valued at $66,034.44. This represents a 36.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired 4,308 shares of company stock valued at $16,594 over the last ninety days. Insiders own 15.00% of the company’s stock.
Profusa Stock Performance
PFSA stock opened at $1.42 on Friday. The stock has a 50-day simple moving average of $3.66 and a 200-day simple moving average of $26.02. The firm has a market cap of $866,200.00, a P/E ratio of -0.00 and a beta of 0.53. Profusa has a 1 year low of $1.40 and a 1 year high of $3,000.00.
Profusa (NASDAQ:PFSA – Get Free Report) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($151.80) earnings per share for the quarter.
Profusa Company Profile
Profusa, Inc is a biotechnology company developing implantable biosensor technology designed to continuously monitor body chemistry. Its sensors are engineered to integrate with tissue and detect selected biological signals, with the goal of providing real-time health data through an external reader or connected digital device.
The company’s technology platform has been studied for applications including monitoring oxygen and other biomarkers that may assist with disease management, clinical research, and personalized healthcare.